Evidence map›Paper›PMID 28203487›Full record

ArticleJournal of clinical & cellular immunology2016

Peroxisome Proliferator-Activated Receptor-γ Agonists: Potential Therapeutics for Neuropathology Associated with Fetal Alcohol Spectrum Disorders.

Paul D Drew, Cynthia J M Kane

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical & cellular immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Paul D DrewDepartment of Neurobiology and Developmental Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Cynthia J M KaneDepartment of Neurobiology and Developmental Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
University of Arkansas for Medical Sciences · US

Funding

Telemedicine CoreP30GM110702 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI GARCIA-RILL, EDGAR E. · 2014 to 2018
$6.1M
Regulation of Neuroimmune Responses in FASD ModelsR01AA024695 · NIAAA · UNIV OF ARKANSAS FOR MED SCIS · PI DREW, PAUL D, KANE, CYNTHIA J. · 2016 to 2020
$1.7M
Microglia modulate ethanol impact on CNS development.R01AA018834 · NIAAA · UNIV OF ARKANSAS FOR MED SCIS · PI KANE, CYNTHIA J. · 2009 to 2013
$1.6M
Neuroinflammatory Mechanisms in FASD: Development of Novel Therapeutic StrategiesR21AA023723 · NIAAA · UNIV OF ARKANSAS FOR MED SCIS · PI KANE, CYNTHIA J. · 2015 to 2016
$391k
NIAAA NIH HHS R01 AA018834NIAAA NIH HHS R01 AA024695NIAAA NIH HHS R21 AA023723NIGMS NIH HHS P30 GM110702
6 · The paper itself

Abstract

Fetal alcohol spectrum disorders (FASD) result from fetal exposure to alcohol during pregnancy. These disorders present a variety of sequelae including involvement of the central nervous system (CNS) with lasting impact on cognitive function and behavior. FASD occur at an alarming rate and have significant personal and societal impact. There are currently no effective treatments for FASD. Recent studies demonstrate that ethanol induces potent neuroinflammation in many regions of the developing brain. Furthermore, anti-inflammatory agents such as peroxisome proliferator-activated receptor (PPAR)-γ agonists suppress ethanol-induced neuroinflammation and neurodegeneration. This suggests that anti-inflammatory agents may be effective in treatment of FASD. Future studies designed to determine the specific mechanisms by which alcohol induces neuroinflammation in the developing CNS may lead to targeted therapies for FASD.

Indexed as

Brain developmentFetal alcohol spectrum disordersNeuroinflammationPeroxisome proliferator-activated receptorsTherapy

Identifiers

PMID28203487
PMCPMC5305275
OpenAlexW2568014240

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.